The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.

Authors: Kerstin Pfister, Thomas W. P. Friedl, Henning Schäffler, Franziska Mergel, Sophia Huesmann, Forca Mehmeti, Natalie Uhl, Angelina Fink, Tatjana Braun, Tanja N. Fehm, Volkmar Mueller, Sabine Heublein, Lisa Maria Wiesmueller, Klaus Pantel, Brigitte Rack, Andreas D. Hartkopf, Peter A. Fasching, Wolfgang Janni

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps622

Source: Full article

---

Abstract

TPS622